Silibinin attenuates cardiac hypertrophy and fibrosis through blocking EGFR-dependent signaling

Journal of Cellular Biochemistry

Volumn 110, Issue 5, 2010, Pages 1111-1122

  Ai, Wen ^a,b   Zhang, Yan ^a,b   Tang, Qi Zhu ^a,b   Yan, Ling ^a,b   Bian, Zhou Yan ^a,b   Liu, Chen ^c   Huang, He ^a,b   Bai, Xue ^a,b   Yin, Lu ^a,b   Li, Hongliang ^a,b  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Cardiac hypertrophy; EGFR; Fibrosis; Signaling pathway; Silibinin

Indexed keywords

ANGIOTENSIN II; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SILIBININ; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; AORTA; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FIBROBLAST; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE OVERLOAD; HEART VENTRICLE PRESSURE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANGIOTENSIN II; ANIMALS; ANIMALS, NEWBORN; BLOTTING, WESTERN; CARDIOMEGALY; CELL SHAPE; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROSIS; GLYCOGEN SYNTHASE KINASE 3; MALE; MICE; MICE, INBRED C57BL; MYOCARDIUM; MYOCYTES, CARDIAC; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SILYMARIN;

ANIMALIA; MUS;

EID: 77954909691     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22623     Document Type: Article

References (37)

1. Bian Z, Cai J, Shen DF, Chen L, Yan L, Tang Q, Li H. 2009. Cellular repressor of E1A-stimulated genes attenuates cardiac hypertrophy and fibrosis. J Cell Mol Med 13:1302-1313.
2. Bueno OF, Molkentin JD. 2002. Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. Circ Res 91:776-781.
3. Chen F, Kook H, Milewski R, Gitler AD, Lu MM, Li J, Nazarian R, Schnepp R, Jen K, Biben C, Runke G, Mackay JP, Novotny J, Schwartz RJ, Harvey RP, Mullins MC, Epstein JA. 2002. Hop is an unusual homeobox gene that modulates cardiac development. Cell 110:713-723.
4. Di Sario A, Bendia E, Taffetani S, Omenetti A, Candelaresi C, Marzioni M, De Minicis S, Benedetti A. 2005. Hepatoprotective and antifibrotic effect of a new silybin-phosphatidylcholine-vitamin E complex in rats. Dig Liver Dis 37:869-876. (Pubitemid 44356117)
5. Duquesnes N, Vincent F, Morel E, Lezoualc'h F, Crozatier B. 2009. The EGF receptor activates ERK but not JNK Ras-dependently in basal conditions but ERK and JNK activation pathways are predominantly Ras-independent during cardiomyocyte stretch. Int J Biochem Cell Biol 41:1173-1181.
6. Ferenci P, Scherzer TM, Kerschner H, Rutter K, Beinhardt S, Hofer H, Schoniger-Hekele M, Holzmann H, Steindl-Munda P. 2008. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 135:1561-1567.
7. Frey N, Katus HA, Olson EN, Hill JA. 2004. Hypertrophy of the heart: A new therapeutic target? Circulation 109:1580-1589.
8. Garcia-Maceira P, Mateo J. 2009. Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: Implications for anticancer therapy. Oncogene 28:313-324.
9. Hamid T, Gu Y, Ortines RV, Bhattacharya C, Wang G, Xuan YT, Prabhu SD. 2009. Divergent tumor necrosis factor receptor-related remodeling responses in heart failure: Role of nuclear factor-kappaB and inflammatory activation. Circulation 119:1386-1397.
10. Hannay JA, Yu D. 2003. Silibinin: A thorny therapeutic for EGF-R expressing tumors? Cancer Biol Ther 2:532-533.
11. Haq S, Choukroun G, Lim H, Tymitz KM, del Monte F, Gwathmey J, Grazette L, Michael A, Hajjar R, Force T, Molkentin JD. 2001. Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation 103:670-677.
12. Homcy CJ. 1998. Signaling hypertrophy: How many switches, how many wires. Circulation 97:1890-1892.
13. Kagiyama S, Qian KP, Kagiyama T, Phillips MI. 2003. Antisense to epidermal growth factor receptor prevents the development of left ventricular hypertrophy. Hypertension 41:824-829. (Pubitemid 36314598)
14. Li HL, Wang AB, Huang Y, Liu DP, Wei C, Williams GM, Zhang CN, Liu G, Liu YQ, Hao DL, Hui RT, Lin M, Liang CC. 2005. Isorhapontigenin, a new resveratrol analog, attenuates cardiac hypertrophy via blocking signaling transduction pathways. Free Radic Biol Med 38:243-257.
15. Li HL, She ZG, Li TB, Wang AB, Yang Q, Wei YS, Wang YG, Liu DP. 2007a. Overexpression of myofibrillogenesis regulator-1 aggravates cardiac hypertrophy induced by angiotensin II in mice. Hypertension 49:1399-1408. (Pubitemid 46809386)
16. Li HL, Zhuo ML, Wang D, Wang AB, Cai H, Sun LH, Yang Q, Huang Y, Wei YS, Liu PP, Liu DP, Liang CC. 2007b. Targeted cardiac overexpression of A20 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circulation 115:1885-1894.
17. Li L, Gao Y, Zhang L, Zeng J, He D, Sun Y. 2008. Silibinin inhibits cell growth and induces apoptosis by caspase activation, down-regulating survivin and blocking EGFR-ERK activation in renal cell carcinoma. Cancer Lett 272:61-69.
18. Liehn EA, Zernecke A, Postea O, Weber C. 2006. Chemokines: Inflammatory mediators of atherosclerosis. Arch Physiol Biochem 112:229-238.
19. Lips DJ, deWindt LJ, van Kraaij DJ, Doevendans PA. 2003. Molecular determinants of myocardial hypertrophy and failure: Alternative pathways for beneficial and maladaptive hypertrophy. Eur Heart J 24:883-896.
20. Liu LJ, Zhao XC, Pierre SV, Askari A. 2007. Association of PI3K-Akt signaling pathway with digitalis-induced hypertrophy of cardiac myocytes. Am J Physiol Cell Physiol 293:C1489-C1497.
21. Rajamanickam S, Kaur M, Velmurugan B, Singh RP, Agarwal R. 2009. Silibinin suppresses spontaneous tumorigenesis in APC (min/+) mouse model by modulating beta-catenin pathway. Pharm Res 26:2558-2567.
22. Ramasamy K, Agarwal R. 2008. Multitargeted therapy of cancer by silymarin. Cancer Lett 269:352-362.
23. Selvetella G, Lembo G. 2005. Mechanisms of cardiac hypertrophy. Heart Fail Clin 1:263-273.
24. Singh RP, Agarwal R. 2006. Prostate cancer chemoprevention by silibinin: Bench to bedside. Mol Carcinog 45:436-442. (Pubitemid 43865852)
25. Singh RP, Tyagi AK, Zhao J, Agarwal R. 2002. Silymarin inhibits growth and causes regression of established skin tumors in SENCAR mice via modulation of mitogen-activated protein kinases and induction of apoptosis. Carcinogenesis 23:499-510. (Pubitemid 34257631)
26. Singh RP, Dhanalakshmi S, Mohan S, Agarwal C, Agarwal R. 2006. Silibinin inhibits UVB- and epidermal growth factor-induced mitogenic and cell survival signaling involving activator protein-1 and nuclear factor-kappaB in mouse epidermal JB6 cells. Mol Cancer Ther 5:1145-1153. (Pubitemid 43881306)
27. Tokuda K, Kai H, Kuwahara F, Yasukawa H, Tahara N, Kudo H, Takemiya K, Koga M, Yamamoto T, Imaizumi T. 2004. Pressure-independent effects of angiotensin II on hypertensive myocardial fibrosis. Hypertension 43:499-503. (Pubitemid 38174161)
28. Turner NA, Mughal RS, Warburton P, O'Regan DJ, Ball SG, Porter KE. 2007. Mechanism of TNFalpha-induced IL-1alpha, IL-1beta and IL-6 expression in human cardiac fibroblasts: Effects of statins and thiazolidinediones. Cardiovasc Res 76:81-90. (Pubitemid 47362045)
29. Tyagi A, Sharma Y, Agarwal C, Agarwal R. 2008. Silibinin impairs constitutively active TGFalpha-EGFR autocrine loop in advanced human prostate carcinoma cells. Pharm Res 25:2143-2150.
30. Verheyen EM. 2007. Opposing effects of Wnt and MAPK on BMP/Smad signal duration. Dev Cell 13:755-756.
31. Wettschureck N, Rutten H, Zywietz A, Gehring D, Wilkie TM, Chen J, Chien KR, Offermanns S. 2001. Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Galphaq/Galpha11 in cardiomyocytes. Nat Med 7:1236-1240.
32. Zhai P, Galeotti J, Liu J, Holle E, Yu X, Wagner T, Sadoshima J. 2006. An angiotensin II type 1 receptor mutant lacking epidermal growth factor receptor transactivation does not induce angiotensin II-mediated cardiac hypertrophy. Circ Res 99:528-536. (Pubitemid 44337825)
33. Zhao J, Agarwal R. 1999. Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: Implications in cancer chemoprevention. Carcinogenesis 20:2101-2108. (Pubitemid 29535311)
34. Zhou B, Wu LJ, Tashiro S, Onodera S, Uchiumi F, Ikejima T. 2006. Silibinin protects rat cardiac myocyte from isoproterenol-induced DNA damage independent on regulation of cell cycle. Biol Pharm Bull 29:1900-1905. (Pubitemid 44338415)
35. Zhou Y, Bourcy K, Kang YJ. 2009. Copper-induced regression of cardiomyocyte hypertrophy is associated with enhanced vascular endothelial growth factor receptor-1 signalling pathway. Cardiovasc Res 84:54-63.
36. Zhu LH, Wang L, Wang D, Jiang H, Tang QZ, Yan L, Bian ZY, Wang XA, Li H. 2010. Puerarin attenuates high-glucose-and diabetes-induced vascular smooth muscle cell proliferation by blocking PKCbeta2/Rac1-dependent signaling. Free Radic Biol Med 48:471-482.
37. Zi X, Zhang J, Agarwal R, Pollak M. 2000. Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells. Cancer Res 60:5617-5620.